WALL STREET KID
5日前
Shifty stock picking as always I see, thank God it's only $6 lost
Message in reply to:🤡
Something is strange too. According to the info. pre Jan. 30th split of this year, after the spilt only 500K shares would exist. So I don't know where these people are fearing a 200 million to 300 million increase when there are no longer 200 million shares post reverse split. See below:
Jan. 28Th 2025 " Once the reverse stock split becomes effective, stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-335 reverse stock split. Existing stockholders holding common stock certificates will receive a letter of transmittal from Aclarion’s transfer agent, Vstock Transfer, with specific instructions regarding the exchange of shares.
The Company expects to have its issued and outstanding common shares decrease from approximately 169.4 million pre-split shares to approximately 500,000 post-split shares outstanding as a result of the reverse stock split.
rbl100
6日前
Something is strange too. According to the info. pre Jan. 30th split of this year, after the spilt only 500K shares would exist. So I don't know where these people are fearing a 200 million to 300 million increase when there are no longer 200 million shares post reverse split. See below:
Jan. 28Th 2025 " Once the reverse stock split becomes effective, stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-335 reverse stock split. Existing stockholders holding common stock certificates will receive a letter of transmittal from Aclarion’s transfer agent, Vstock Transfer, with specific instructions regarding the exchange of shares.
The Company expects to have its issued and outstanding common shares decrease from approximately 169.4 million pre-split shares to approximately 500,000 post-split shares outstanding as a result of the reverse stock split.
About Aclarion, Inc."
makinezmoney
1週前
$ACON: Not sure why it really fell though......................
News out.......... don't see anything that would cause it...........
Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York and New Jersey. The expansion plans build on previously established Nociscan sites with RadNet affiliates in both states and are driven by the increased availability of MR Spectroscopy (MRS) and enhanced remote operations capabilities within RadNet to meet growing market demand for Nociscan. "Expanding scanner access is a key element of our strategy to drive Nociscan to standard of care for patients with chronic low back pain," said Brent Ness, Chief Executive Officer of Aclarion. "The additional sites RadNet is onboarding will help us enable more convenient access to grow scan volume in response to physician demand. It also underscores our strong relationship with this important national imaging provider." Lenox Hill Radiology (LHR) operates convenient, outpatient imaging centers located in the metropolitan New York area, and 79 total locations throughout New York state. LHR Park Avenue, a flagship site, initially adopted Nociscan to provide access to leading spine physicians in private practice and from globally recognized organizations such as Weill Cornell. New Jersey Imaging Network (NJIN) is one of the largest imaging providers in NJ with 33 locations. NJIN-Union, in metro NJ, was the first site in NJ to adopt Nociscan to support both local physicians and out-of-market referrals through the convenience of Newark Liberty International Airport and Teterboro Airport. Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain and demonstrates a 97% surgical success rate when all Nociscan-identified pain positive discs are treated.